CenterWatch.com/clinical-trials/listings 218732 Pr
Post# of 148187
(Total Views: 795)
Posted On: 05/23/2023 10:59:06 PM
CenterWatch.com/clinical-trials/listings 218732 Pro14
Pro140 in treatment experienced HIV-1 Subjects
Participants: 25
Status: (Not recruiting)
Updated on: 23rd May/2023
DETAILS:
Condition: HIV-1-infection
Treatment: Pro140
Clinical study
Identifier: NCT03902522
Sponsor: Cytodyn, Inc.....Last modified: 23 May 2023
SUMMARY:
The primary objectives of the trial are to assess the EfficacyClinical Safety and Tolerability parameters of PRO140 in combination with failing ART during the initial one-week treatment period and in combination with Optimized Background Therapy during the subsequent 24-week treatment period.
Pro140 in treatment experienced HIV-1 Subjects
Participants: 25
Status: (Not recruiting)
Updated on: 23rd May/2023
DETAILS:
Condition: HIV-1-infection
Treatment: Pro140
Clinical study
Identifier: NCT03902522
Sponsor: Cytodyn, Inc.....Last modified: 23 May 2023
SUMMARY:
The primary objectives of the trial are to assess the EfficacyClinical Safety and Tolerability parameters of PRO140 in combination with failing ART during the initial one-week treatment period and in combination with Optimized Background Therapy during the subsequent 24-week treatment period.
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼